ENVISION
Research type
Research Study
Full title
Envision
IRAS ID
301130
Contact name
David Brealey
Contact email
Sponsor organisation
Löwenstein Medical Innovation GmbH & Co. KG
Duration of Study in the UK
0 years, 6 months, 30 days
Research summary
Managing a COVID-19 patient in need of intensive care is highly complex. At this point, the disease is multi-system involving not just incredibly resistant respiratory failure but also often involving shock, right heart failure and kidney failure. Complications such as secondary infection and venous thrombosis are also common. Mortality is high, ranging from 30-40% for those on invasive ventilation. The difficulties are compounded, in surges, by the sheer numbers of patients and the relative lack of qualified staff. Many hospitals drafting in doctors and nurses from other specialities, administrators and medical students to help manage these patients. This dilutes specialist knowledge, reduces quality of care and increase the risk of error when compared to normal practice. This project aims to develop an intelligent 'plug and play' tool (Sandman.ICU) for full time data monitoring of COVID-19 patients in the ICU and the development of an artificial intelligence for assisting in the treatment of severe COVID. The ultimate aim is for the system to then alert and advise the clinicians about the best way forward in managing the patient in front of them. In this way reducing the information overload and only highlighting relevant issues we hope to improve the quality of care and reduce the incidence of error. This application relates only to the collection of patient data, development of the monitoring system and training of the AI algorithm. This project will not investigate the impact of the system on patient care.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
22/EE/0051
Date of REC Opinion
28 Mar 2022
REC opinion
Further Information Favourable Opinion